Breaking News

  • 8 hours ago

  • Vaibhavi M.

Greenwich LifeSciences Reports Promising Phase III Data For FLAMINGO-01 Trial Evaluating GLSI-100, Showing Significant Drop In Breast Cancer Recurrence Rates
Breaking News

More News

ImmunityBio’s ANKTIVA Plus BCG Added To NCCN 2026 Guidelines For Broader Bladder Cancer Use

ImmunityBio’s ANKTIVA Plus BCG Added To NCCN 2026 Guidelines For Broad...

Vaibhavi M.

Neuronetics Appoints Medtech Veteran Dan Reuvers As Chief Executive Officer, Succeeding Keith Sullivan

Neuronetics Appoints Medtech Veteran Dan Reuvers As Chief Executive Of...

Vaibhavi M.

HCW Biologics Secures $7M Upfront License Payment From Beijing Trimmune Biotech, Advanced China Licensing Deal For HCW11-006

HCW Biologics Secures $7M Upfront License Payment From Beijing Trimmun...

Vaibhavi M.

Ascendis Pharma Reports Positive Phase 2 Results For Weekly TransCon hGH In Turner Syndrome

Ascendis Pharma Reports Positive Phase 2 Results For Weekly TransCon h...

Vaibhavi M.

Ad
Advertisement

Interviews & Opinions

Article

“Be Proactive, Not Reactive” - Dr. ARM Rao’s Leadership Philosophy

In this exclusive leadership conversation, Dr. ARM Rao, President of Aurobindo Pharmaceuticals, shares insights from his 35+ year journey in pharma. F...

FT - Dr. A. R. M. Rao

Read More

Ad
Advertisement
Pharma Now

Weekly Pharma insights directly in your inbox

Get most important news delivered to your email inbox

Pharma Now

Weekly Pharma insights directly in your inbox

Get most important news delivered to your email inbox

Ad
Advertisement

Pharma Shorts